Neurosense Therapeutics Ltd (NRSN) Stock Price, Quote & News

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 9 799 6183

Website: www.neurosense-tx.com

Address:

Building B, 11 HaMenofim Street, Herzliya, Israel

SkyLonger Sep. 14 at 5:21 PM

$NRSN lets touch $5+ Monday or this week 🤙 soon enough

0 · Reply

Zofar Sep. 14 at 12:12 PM

$NRSN represents

1 · Reply

millionaire_ST Sep. 13 at 10:33 PM

$NRSN wouldnt surprise me to start seeing the share price incrementally move North from here until partnership is announced. Last weeks news was incredible and is helping solidify prime c role in treating ALS. Slow and steady upwards move cound return 2%-5% a day for the foreseeable future imho. 0 shares to short and only 29 million market cap is incredibly low

0 · Reply

Stekli27 Sep. 13 at 9:38 PM

$NRSN Warren Buffett said: “The best thing that happens to us is when a great company gets into temporary trouble. We want to buy them when they’re on the operating table.” NeuroSense is exactly there right now, great data, validated manufacturing, survival benefit, and a partner very likely around the corner. Market doesn’t trust them, but that’s when you buy. I’m loading before the partnership announcement hits.

2 · Reply

millionaire_ST Sep. 13 at 9:11 PM

$NRSN Its explained quite well in the video posted. Third party complications out of their control. Those things have been resolved and now conclusion and signing are imminent

0 · Reply

elmono Sep. 13 at 9:06 PM

$NRSN it’s been imminent for almost a year now 😂😂😂🤷‍♂️

0 · Reply

millionaire_ST Sep. 13 at 3:15 PM

$NRSN a good partnership should put NRSN on the map with 150 million market cap or more. 400% is a starter or $6.00. Most analysts price targets start $7.50 and head north of $10 up to $14.00

0 · Reply

millionaire_ST Sep. 13 at 3:03 PM

$NRSN https://www.reddit.com/r/ALS/comments/1mkqz7p/aaron_lazar_alon_bennoon_on_fighting_als/ Start listening around the 27 minute mark. The partnership is imminent imho

0 · Reply

millionaire_ST Sep. 12 at 11:01 PM

$NRSN 2 million to go up 7% and strangely only 15 thousand to take it back to where it started this morning. Own a few thousand shares now for a lotto ticket. Wish you all the very best. Hopefully Alon pulls through. Sounds like its pretty much complete as per his latest interview. Starts at the 26 minute mark if youre interested $14 or bust

1 · Reply

stevelue Sep. 12 at 8:31 PM

$NRSN give me $10-$14 pps on $NRSN news next week! Cheers!

0 · Reply

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

Sep 4, 2025, 8:49 AM EDT - 10 days ago

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

Aug 1, 2025, 9:00 AM EDT - 6 weeks ago

NeuroSense Provides Business Update and Progress for the First Half of 2025

Jul 22, 2025, 8:42 AM EDT - 7 weeks ago

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

May 12, 2025, 3:08 PM EDT - 4 months ago

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 7, 2025, 8:45 AM EDT - 4 months ago

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

Apr 24, 2025, 9:09 AM EDT - 5 months ago

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

Apr 9, 2025, 8:30 AM EDT - 5 months ago

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Apr 7, 2025, 5:14 PM EDT - 5 months ago

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

Apr 4, 2025, 9:10 AM EDT - 5 months ago

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Mar 17, 2025, 8:30 AM EDT - 6 months ago

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Jan 6, 2025, 9:00 AM EST - 8 months ago

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

Dec 23, 2024, 9:00 AM EST - 9 months ago

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Dec 18, 2024, 10:25 AM EST - 9 months ago

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

Dec 11, 2024, 9:25 AM EST - 9 months ago

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

Dec 4, 2024, 8:30 AM EST - 10 months ago

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

Dec 2, 2024, 8:30 AM EST - 10 months ago

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

Nov 21, 2024, 9:20 AM EST - 10 months ago

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

Oct 28, 2024, 8:30 AM EDT - 11 months ago

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

Oct 24, 2024, 8:30 AM EDT - 11 months ago

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

Oct 15, 2024, 9:15 AM EDT - 11 months ago

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

Oct 9, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

Oct 7, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

Sep 24, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

Sep 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Aug 30, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Aug 7, 2024, 2:00 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

Aug 1, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

Jul 9, 2024, 9:27 AM EDT - 1 year ago

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

Jul 2, 2024, 12:34 PM EDT - 1 year ago

This cheap biotech offers investors a play on ALS if trial data continues to impress

Jul 1, 2024, 8:00 AM EDT - 1 year ago

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

Jun 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

Jun 21, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

May 20, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

May 14, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

May 7, 2024, 8:45 AM EDT - 1 year ago

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

May 2, 2024, 9:19 AM EDT - 1 year ago

NeuroSense Announces First Quarter 2024 Business Update

Apr 22, 2024, 8:30 AM EDT - 1 year ago

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

Apr 18, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

Apr 12, 2024, 8:30 AM EDT - 1 year ago

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

Apr 10, 2024, 7:16 PM EDT - 1 year ago

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

Apr 9, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

Apr 5, 2024, 9:29 AM EDT - 1 year ago

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

Feb 21, 2024, 8:30 AM EST - 1 year ago

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

Jan 30, 2024, 8:30 AM EST - 1 year ago

NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

BIIB

Jan 9, 2024, 8:45 AM EST - 1 year ago

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

Dec 27, 2023, 5:00 PM EST - 1 year ago

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Dec 14, 2023, 9:24 AM EST - 1 year ago

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

Dec 5, 2023, 8:00 AM EST - 1 year ago

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

SkyLonger Sep. 14 at 5:21 PM

$NRSN lets touch $5+ Monday or this week 🤙 soon enough

0 · Reply

Zofar Sep. 14 at 12:12 PM

$NRSN represents

1 · Reply

millionaire_ST Sep. 13 at 10:33 PM

0 · Reply

Stekli27 Sep. 13 at 9:38 PM

2 · Reply

millionaire_ST Sep. 13 at 9:11 PM

$NRSN Its explained quite well in the video posted. Third party complications out of their control. Those things have been resolved and now conclusion and signing are imminent

0 · Reply

elmono Sep. 13 at 9:06 PM

$NRSN it’s been imminent for almost a year now 😂😂😂🤷‍♂️

0 · Reply

millionaire_ST Sep. 13 at 3:15 PM

$NRSN a good partnership should put NRSN on the map with 150 million market cap or more. 400% is a starter or $6.00. Most analysts price targets start $7.50 and head north of $10 up to $14.00

0 · Reply

millionaire_ST Sep. 13 at 3:03 PM

$NRSN https://www.reddit.com/r/ALS/comments/1mkqz7p/aaron_lazar_alon_bennoon_on_fighting_als/ Start listening around the 27 minute mark. The partnership is imminent imho

0 · Reply

millionaire_ST Sep. 12 at 11:01 PM

1 · Reply

stevelue Sep. 12 at 8:31 PM

$NRSN give me $10-$14 pps on $NRSN news next week! Cheers!

0 · Reply

Busey Sep. 12 at 7:56 PM

$NRSN 4x avg volume. 0 shares available to short.😁

0 · Reply

millionaire_ST Sep. 12 at 7:46 PM

$NRSN partnership with this low float will be a record in parabolic rise. 500% in a single day isnt off the table. Short term pt $14.00

0 · Reply

stevelue Sep. 12 at 7:35 PM

$NRSN $1.30 by eod, and $1.40-$1.50 in AH today...News is coming next week likely imo

0 · Reply

ACstranger Sep. 12 at 6:32 PM

$NRSN next week...

0 · Reply

stevelue Sep. 12 at 6:31 PM

$NRSN Monday news incoming? end of day and AH today could be interesting....Cheers!

1 · Reply

millionaire_ST Sep. 12 at 5:20 PM

$NRSN $200 plus a share on only 1 billion sales here 👀

1 · Reply

stevelue Sep. 12 at 4:23 PM

$NRSN Big News on Pharma partner next week imo...We close $1.30-$1.40.....LETS go!

0 · Reply

ZippedCookie Sep. 12 at 4:08 PM

$NRSN Great close on last 1hr candle. Maybe runs up a bit into AH

0 · Reply

sc77 Sep. 12 at 3:58 PM

$NRSN Big news soon

0 · Reply

Zofar Sep. 12 at 3:24 PM

$NRSN

2 · Reply

millionaire_ST Sep. 12 at 3:07 PM

$NRSN very good chance we are headed back to $2.50 area short term. ALS data here is a worlds first and is easy to manufacture primec. Listened to the conference Alon had with celebrity Aaron Lazar. Around 26 minutes he speaks of things out of his control but goes on to state a partnership is imminent and both sides want to complete. I believe we have a partnership. Looking for $14 on that news

0 · Reply

stevelue Sep. 12 at 2:59 PM

$NRSN

0 · Reply

Market Cap	16.67M
Revenue (ttm)	0.00
Net Income (ttm)	-10.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,129,000
Avg Vol	756,554
Day's Range	N/A - N/A
Shares Out	13.67M
Stochastic %K	26%
Beta	1.58
Analysts	Sell
Price Target	$10.75